Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic partnership to further develop the artificial intelligence-enabled ClinTech Platform.

Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform

Photo by Pietro Jeng on Pexels

The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centered biopharmaceutical ecosystem. It also follows the integration of Citeline’s SmartSolutions into the Recursion platform to provide data access during early development stages.

The expanded partnership paves the way for integrating Citeline’s real-world data and evidence capabilities into Recursion’s end-to-end platform. The integration will strengthen the platform’s foundation, enabling more precise trial design, improved site selection, and informed development decisions.

The addition of Citeline’s data and evidence capabilities to the company’s robust platform is also poised to support pipeline development. The ClinTech platform is already yielding results, including 30%-60% improvements in enrollment, affirming the importance of integration.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage “TechBio” company that uses artificial intelligence (AI), machine learning, automation, and high-throughput biology to enhance drug discovery and development.

While we acknowledge the risk and potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.